-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Initiates Coverage On Kalaris Therapeutics with Outperform Rating, Announces Price Target of $17

Benzinga·05/14/2026 13:04:59
Listen to the news
Wedbush analyst Yun Zhong initiates coverage on Kalaris Therapeutics (NASDAQ:KLRS) with a Outperform rating and announces Price Target of $17.